News · 26 weeks51+50%
2026-04-122026-10-04
Mix1790d
- SEC Filings7(41%)
- Other7(41%)
- Earnings2(12%)
- Analyst1(6%)
Latest news
25 items- PRArvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers – – Findings support continued evaluation of ARV-102 as a potential therapeutic approach for neurodegenerative diseases associated with LRRK2 dysregulation – NEW HAVEN, Conn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today presented novel data from a Phase 1 clinical trial of ARV-102, an inves
- PRArvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease will be presented as late-breaking oral and poster presentations at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® (MDS), taking place October 4-8, 2026, in Seoul, Korea. ARV-102 is Arvinas’ investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) degrader designed to cross the blood-brain barrier and target leucine-rich repeat kin
- PRArvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) ("Arvinas" or the "Company"), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the "Option Award") and 42,388 restricted stock units ("RSU") to one newly hired employee (the "RSU Award"). The Option Award and RSU Award were each granted as of September 28, 2026 (the "Grant Date") in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan. The option has a 10-year term and an exercise price of $7.51 per share, which is equal
- SECSEC Form S-8 filed by Arvinas Inc.S-8 - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors. ARV-6723 is Arvinas’ first clinical candidate in immuno-oncology (IO) and the first HPK1 PROTAC degrader to ent
- SECSEC Form 144 filed by Arvinas Inc.144 - ARVINAS, INC. (0001655759) (Subject)
- SECSEC Form 144 filed by Arvinas Inc.144 - ARVINAS, INC. (0001655759) (Subject)
- PRArvinas to Participate in Upcoming Investor ConferencesNEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) ("Arvinas" or the "Company"), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences: Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 1:30 p.m. ET; webcast available here. Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 2:10 p.m. ET; webcast available here. Morgan Stanley Annual Global Healthcare Conference on Wednesday, September 16, 2026, at 9:15 a.m. ET; webcast available here. All webcasts wi
- PRArvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) ("Arvinas" or the "Company"), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units ("RSU") to one newly hired employee (the "RSU Award"). The RSU Award was granted as of August 31, 2026 (the "Grant Date") and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan. The RSU Award will vest in full on the one-year anniversary of the date of grant. The vesting of the RSU Award is subject to the employee's continued service as an employee of, or other
- SECSEC Form S-8 filed by Arvinas Inc.S-8 - ARVINAS, INC. (0001655759) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.SCHEDULE 13G/A - ARVINAS, INC. (0001655759) (Subject)
- SECSEC Form 144 filed by Arvinas Inc.144 - ARVINAS, INC. (0001655759) (Subject)
- SECSEC Form 10-Q filed by Arvinas Inc.10-Q - ARVINAS, INC. (0001655759) (Filer)
- ANALYSTArvinas downgraded by Wells FargoWells Fargo downgraded Arvinas from Overweight to Equal Weight
- SECArvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based
- PRArvinas to Report Second Quarter 2026 Financial Results on August 4, 2026NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About Arvinas Arvinas (NASDAQ:ARVN) is a biotechnology company dedicated to improving the lives of patients suffe
- SECSEC Form 144 filed by Arvinas Inc.144 - ARVINAS, INC. (0001655759) (Subject)
- INSIDERDirector Smaldone Alsup Laurie was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Norwalk Leslie V was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Morrison Briggs was granted 15,527 shares, increasing direct ownership by 16% to 111,548 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Kennedy Edward Moore Jr. was granted 15,527 shares, increasing direct ownership by 39% to 54,957 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Cunningham Everett was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Bain Linda was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- SECArvinas Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ARVINAS, INC. (0001655759) (Filer)
ARVN FAQ
7 questionsWhat does Arvinas Inc. do?
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The...Where does ARVN stock trade?
Arvinas Inc. (ARVN) is listed on NASDAQ.What sector and industry is ARVN in?
Arvinas Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arvinas Inc. go public?
Arvinas Inc. (ARVN) completed its IPO in 2018.What are analysts saying about ARVN?
Arvinas Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Equal Weight on 2026-08-04. Recent price targets range from $600.00 to $1600.00.What companies are similar to ARVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ARVN side-by-side with any of them on Quantisnow.How can I track ARVN on Quantisnow?
Quantisnow aggregates Arvinas Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARVN to receive live email and push alerts on every new disclosure.